Ballentine Partners LLC purchased a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 615 shares of the medical research company’s stock, valued at approximately $213,000.
A number of other large investors have also recently made changes to their positions in the stock. Norges Bank purchased a new position in shares of Bio-Rad Laboratories in the fourth quarter worth approximately $73,142,000. Parsifal Capital Management LP purchased a new position in shares of Bio-Rad Laboratories in the fourth quarter worth approximately $61,866,000. Deerfield Management Company L.P. Series C purchased a new position in shares of Bio-Rad Laboratories in the third quarter worth approximately $62,351,000. Goldman Sachs Group Inc. boosted its holdings in shares of Bio-Rad Laboratories by 454.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 144,333 shares of the medical research company’s stock worth $46,604,000 after buying an additional 118,304 shares during the last quarter. Finally, Earnest Partners LLC boosted its holdings in shares of Bio-Rad Laboratories by 25.6% in the third quarter. Earnest Partners LLC now owns 351,510 shares of the medical research company’s stock worth $125,999,000 after buying an additional 71,570 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In related news, EVP Michael Crowley sold 369 shares of the business’s stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $281.91, for a total value of $104,024.79. Following the sale, the executive vice president now owns 6,573 shares in the company, valued at $1,852,994.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 17.06% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on BIO
Bio-Rad Laboratories Price Performance
BIO stock opened at $278.16 on Thursday. Bio-Rad Laboratories, Inc. has a one year low of $261.59 and a one year high of $431.79. The company’s fifty day moving average price is $284.34 and its 200-day moving average price is $310.89. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.89 and a current ratio of 6.57. The company has a market capitalization of $7.93 billion, a PE ratio of -26.85 and a beta of 0.95.
Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last released its earnings results on Tuesday, May 7th. The medical research company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.04 by $0.25. Bio-Rad Laboratories had a negative net margin of 12.37% and a positive return on equity of 3.59%. The firm had revenue of $610.82 million for the quarter, compared to the consensus estimate of $619.09 million. During the same quarter in the previous year, the firm earned $3.34 earnings per share. The company’s quarterly revenue was down 9.8% compared to the same quarter last year. On average, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.8 EPS for the current fiscal year.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Featured Stories
- Five stocks we like better than Bio-Rad Laboratories
- The Significance of Brokerage Rankings in Stock Selection
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- 5 discounted opportunities for dividend growth investors
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.